EA202090569A1 - Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени - Google Patents

Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени

Info

Publication number
EA202090569A1
EA202090569A1 EA202090569A EA202090569A EA202090569A1 EA 202090569 A1 EA202090569 A1 EA 202090569A1 EA 202090569 A EA202090569 A EA 202090569A EA 202090569 A EA202090569 A EA 202090569A EA 202090569 A1 EA202090569 A1 EA 202090569A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alcoholic
liver
steathepatitis
dystrophies
fatal
Prior art date
Application number
EA202090569A
Other languages
English (en)
Inventor
Реми Анф
Женевьев Кордоннье
Джон Брозек
Original Assignee
Женфит
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Женфит filed Critical Женфит
Priority claimed from PCT/EP2018/073050 external-priority patent/WO2019038456A1/en
Publication of EA202090569A1 publication Critical patent/EA202090569A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к новому неинвазивному способу диагностики неалкогольной жировой дистрофии печени, в частности неалкогольного стеатогепатита и/или фиброза печени.
EA202090569A 2017-11-03 2018-08-27 Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени EA202090569A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17200028 2017-11-03
PCT/EP2018/073050 WO2019038456A1 (en) 2017-08-25 2018-08-27 NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS

Publications (1)

Publication Number Publication Date
EA202090569A1 true EA202090569A1 (ru) 2020-06-03

Family

ID=60421559

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090569A EA202090569A1 (ru) 2017-11-03 2018-08-27 Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени

Country Status (1)

Country Link
EA (1) EA202090569A1 (ru)

Similar Documents

Publication Publication Date Title
EA202090715A1 (ru) Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени
PH12020500164A1 (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
EA201892201A1 (ru) Неинвазивная диагностика неалкогольного стеатогепатита
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
EA201690199A1 (ru) Лекарственное средство для лечения неалкогольной жировой болезни печени
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
WO2015138532A3 (en) Methods for the treatment of kidney fibrosis
EP3285071A4 (en) Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method
SG11202102684VA (en) Treatment for non-alcoholic fatty liver disease
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
GB201804724D0 (en) Method of diagnosing cceliac disease
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение
BR112016015712A2 (pt) método de tratamento de doenças hepáticas.
WO2017029558A3 (en) Methods for improving health of farmed fish
WO2016183223A3 (en) Targeted protein contrast agents, methods of making, and uses thereof
EA202090569A1 (ru) Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени
MX2017006747A (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.